Abstract

Background and Aims: The WHO has solicited all countries to eliminate HCV by 2030. The Italian government started routine screening for HCV infection in January 2021, initially targeting subjects born between 1969 and 1989. With the aim of achieving micro-elimination, we designed a hospital-wide project focusing on inpatients born from 1935 to 1985 and conducted it in our institution. Method: All inpatients aged 35 to 85, admitted from 10 February 2020 to 9 February 2021 for many different diseases and conditions underwent HCV antibody (HCVAb) testing by third-generation ELISA. When positive, reflex HCV RNA testing and genotyping were performed. Clinical history, fibrosis diagnosis, laboratory data and concomitant medications were available for all. Results: The HCV screening rate of inpatients was 100%. In total, 11,748 participants were enrolled, of whom 53.50% were male. The HCVAb positivity rate was 3.03%. The HCVAb rate increased with age and was higher for patients born between 1935 and 1944 (4.81%). The rate of HCV RNA positivity was 0.97%. The vast majority (80.70%) of HCV RNA-positive participants were 55 or older; in about 40% of cases, HCV RNA-positive patients were unaware of their infection. Although 16 patients died after HCV chronic infection diagnosis (two due COVID-19) or HCV treatment prescription (one due to COVID-19), 74.56% of patient HCV diagnoses were linked to HCV treatment, despite their co-morbidities. All patients older than 65 who died had an active HCV infection. Conclusion: The present study revealed a rate of active HCV infections among inpatients lower than what has been reported in the past in the general population; this appears to be a result of the widespread use of pangenotypic direct-acting antiviral agents (DAAs). The overall rate of active infection was lower than the rate observed in the 1935–1954 cohort. The high rate of inpatients unaware of HCV infections and the high number of deaths among subjects with an active HCV infection born from 1935 to 1954, suggest that, at least in southern Italy, targeted screening of this birth cohort may be required to reduce the number of undiagnosed cases and hidden infections.

Highlights

  • Hepatitis C virus (HCV) affects more than 71 million people worldwide, representing a serious public health issue

  • The positivity rate increased with age, confirming the already-known birth cohort effect associated with HCV infection in Italy [13,15]

  • Part of the study success was linked to the opportunity to monitor patients using telehealth during the COVID-19 pandemic

Read more

Summary

Introduction

Hepatitis C virus (HCV) affects more than 71 million people worldwide, representing a serious public health issue. Based on the efficacy of new DAAs, ensuring viral clearance in more than 95% of treated patients, the WHO has promoted the Global Sectorial Strategy for HCV elimination by 2030, with the ambitious objective of increasing diagnosis to. Chronic HCV infection can remain asymptomatic until the latest stages, leading to poor awareness of patient’s infection status and to a significant proportion of undiagnosed diseases. In Europe, 60% of all HCVinfected patients remain undiagnosed, with considerable differences across countries [2]. Key aspects preventing HCV elimination are the lack of reliable and updated estimates of active HCV infections and related disease burdens across Europe [3]. The WHO has solicited all countries to eliminate HCV by 2030. With the aim of achieving micro-elimination, we designed a hospital-wide project focusing on inpatients born from 1935 to 1985 and conducted it in our institution

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call